Company / FCF Margin
SAB Biotherapeutics, Inc. FCF Margin History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
-2618.7%
FY2025
5-year range
-2618.7% / -4.9%
FY2021-FY2025
Trend
-131.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
FCF Margin has declined for 4 consecutive years, from -4.9% in FY2021 to -2618.7% in FY2025.
Based on SEC 10-K filings.
-2618.7% in FY2025 with a 3-year CAGR of -2603.9%.
Declined from -107.2% to -2618.7% over the past 2 years.
FCF Margin over time
Growth rates
- 3-Year Change
- -2603.9pp
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- SAB Biotherapeutics, Inc.'s fcf margin has declined for 4 consecutive years.
- In FY2025, fcf margin decreased 131.6% year-over-year.
- Peak fcf margin was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.31 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -2618.7% | -131.6% |
| FY2024 | -1130.7% | -954.8% |
| FY2023 | -107.2% | -628.8% |
| FY2022 | -14.7% | -197.8% |
| FY2021 | -4.9% | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026